Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting | ||
By: GlobeNewswire - 18 Apr 2024 | Back to overview list |
|
WILMETTE, Ill., April 18, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that its abstract on the preclinical data for its radiopharmaceutical program MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) submitted to the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting has been selected for a presentation. SNMMI 2024, held in Toronto, Canada, is recognized as the premier educational, scientific, and research event in the radiopharma space. Meeting Details: Event: Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting Date: June 8 – June 11, 2024 Location: Metro Toronto Convention Centre, Toronto, ON, Canada About Monopar Therapeutics Inc. Monopar?Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar's?pipeline consists of Phase 1-stage MNPR-101 for radiopharmaceutical use in various advanced cancers; Phase 1b-stage camsirubicin?for the treatment?of advanced soft tissue sarcoma; and an early-stage camsirubicin analog, MNPR-202. For more information, visit: www.monopartx.com and ir.monopartx.com/presentations. CONTACT: Monopar Therapeutics Inc. Follow Monopar on social media for updates: Twitter: @MonoparTx LinkedIn: Monopar Therapeutics |
||
|
||
Copyright 2024 GlobeNewswire | Back to overview list |